Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ pharmacology
Drug Synergism
Female
Humans
Leukocytes, Mononuclear
/ drug effects
Male
Middle Aged
Myeloproliferative Disorders
/ drug therapy
Nitriles
Prednisone
/ administration & dosage
Primary Myelofibrosis
/ drug therapy
Prognosis
Protein Array Analysis
Pyrazoles
/ administration & dosage
Pyrimidines
/ administration & dosage
Tumor Cells, Cultured
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
10
07
2018
accepted:
10
12
2018
pubmed:
14
12
2018
medline:
21
5
2020
entrez:
15
12
2018
Statut:
ppublish
Résumé
Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the adverse effects of this drug, we evaluated the combination of 17 drugs with ruxolitinib in
Identifiants
pubmed: 30545926
pii: haematol.2018.201038
doi: 10.3324/haematol.2018.201038
pmc: PMC6518898
doi:
Substances chimiques
Nitriles
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
nilotinib
F41401512X
Prednisone
VB0R961HZT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
937-946Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Lancet. 2005 Mar 19-25;365(9464):1054-61
pubmed: 15781101
Blood. 2007 Jul 1;110(1):345-53
pubmed: 17374740
J Clin Invest. 2010 Oct;120(10):3578-93
pubmed: 20852385
Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):305-18
pubmed: 24468131
Haematologica. 2015 Aug;100(8):1058-63
pubmed: 26088933
Am J Clin Oncol. 2016 Feb;39(1):76-84
pubmed: 24351780
Ann Lab Med. 2015 Jan;35(1):22-7
pubmed: 25553276
Blood. 2017 Feb 9;129(6):667-679
pubmed: 28028029
Clin Cancer Res. 2013 Nov 15;19(22):6230-41
pubmed: 24081976
Br J Haematol. 2017 Mar;176(6):939-949
pubmed: 28220932
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Leukemia. 2008 Jan;22(1):14-22
pubmed: 17882280
Blood. 2011 Mar 31;117(13):3494-504
pubmed: 21200024
Blood. 2016 Mar 10;127(10):1317-24
pubmed: 26608331
J Biol Chem. 2005 Jun 17;280(24):22788-92
pubmed: 15863514
Haematologica. 2015 Sep;100(9):1139-45
pubmed: 26069290
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Ann Hematol. 2015 Nov;94(11):1791-6
pubmed: 26122869
F1000Res. 2018 Jan 17;7:82
pubmed: 29399328
N Engl J Med. 2015 Sep 3;373(10):908-19
pubmed: 26332545
Leuk Res. 2017 Sep;60:31-35
pubmed: 28646676
Pharm Biol. 2017 Dec;55(1):450-455
pubmed: 27937011
J Hematol Oncol. 2017 Sep 29;10(1):156
pubmed: 28962635
Blood. 2014 Aug 28;124(9):1492-501
pubmed: 24957147
Am J Hematol. 2010 Aug;85(8):616-9
pubmed: 20540156
N Engl J Med. 2013 Dec 19;369(25):2391-2405
pubmed: 24325359
Expert Rev Hematol. 2017 Feb;10(2):155-159
pubmed: 27983880
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Nat Med. 2015 Jul;21(7):786-94
pubmed: 26053624
Arthritis Rheumatol. 2016 Sep;68(9):2263-73
pubmed: 27111463
Blood. 2016 Mar 10;127(10):1325-35
pubmed: 26668133
Pharmacol Rev. 2006 Sep;58(3):621-81
pubmed: 16968952
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
FASEB J. 2008 Jul;22(7):2214-22
pubmed: 18326784
Blood. 2013 Jun 13;121(24):4832-7
pubmed: 23570800
J Transl Med. 2017 Aug 30;15(1):184
pubmed: 28854975
J Hepatol. 2011 Sep;55(3):612-625
pubmed: 21251937
Blood. 2008 Oct 15;112(8):3026-35
pubmed: 18669872
Diagn Mol Pathol. 2011 Mar;20(1):34-9
pubmed: 21326037
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187